Auxilium Pharmaceuticals Rating Increased to Buy at MKM Partners (AUXL)
Auxilium Pharmaceuticals (NASDAQ:AUXL) was upgraded by stock analysts at MKM Partners from a “neutral” rating to a “buy” rating in a report issued on Tuesday, TheFlyOnTheWall.com reports.
Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 17.90 on Tuesday. Auxilium Pharmaceuticals has a 52-week low of $13.87 and a 52-week high of $25.54. The stock has a 50-day moving average of $18.22 and a 200-day moving average of $16.95. The company has a market cap of $882.4 million and a P/E ratio of 6.86.
Auxilium Pharmaceuticals (NASDAQ:AUXL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.03) by $0.05. The company had revenue of $100.50 million for the quarter, compared to the consensus estimate of $91.43 million. During the same quarter last year, the company posted $0.16 earnings per share. Auxilium Pharmaceuticals’s revenue was up 28.5% compared to the same quarter last year. Analysts expect that Auxilium Pharmaceuticals will post $0.46 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on AUXL. Analysts at R. F. Lafferty initiated coverage on shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) in a research note to investors on Thursday, August 29th. They set a “buy” rating and a $23.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) from $25.00 to $27.00 in a research note to investors on Friday, August 2nd. They now have a “buy” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) from $20.00 to $23.00 in a research note to investors on Friday, August 2nd. They now have a “buy” rating on the stock.
Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.14.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.